Press Release
« Back
TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
Sep 28, 2018
The Cantor Fitzgerald Global Healthcare Conference , onMonday, October 1, 2018 at2:20pm ET , being held at theInterContinental New York Barclay Hotel inNew York City .- The Ladenburg Thalmann 2018 Healthcare Conference, on
Tuesday, October 2, 2018 at1:00pm ET , being held at theSofitel New York Hotel , also inNew York City .
A live webcast of each presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B‐lymphocytes. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought its anti-PD-L1 monoclonal antibody into Phase 1 development and aims to bring additional pipeline assets into the clinic in the future. TG Therapeutics is headquartered in New York City.
CONTACT:
Senior Vice President,
Corporate Communications
Telephone: 212.554.4351
Email: ir@tgtxinc.com
Source: TG Therapeutics, Inc.